Teva shareholders may sue over EU Copaxone affair

Teva drug Copaxone  credit: Tamar Matsafi
Teva drug Copaxone credit: Tamar Matsafi

Shareholders have filed petitions in the Tel Aviv District Court for document discovery in preparation for a possible derivative action.

Shareholders in Teva Pharmaceutical Industries (TASE: TEVA; NYSE: TEVA) filed four petitions for discovery of documents in the Tel Aviv District Court last week, for the purposes of a derivative action against the company. This follows the publication of initial findings of an antitrust investigation by the EU Commission.

In a letter from the Commission to Teva, the company is alleged to have violated EU antitrust laws in practices delaying competition for its multiple sclerosis treatment Copaxone. Among other things, the European Commission alleges that Teva artificially extended Copaxone's patent and distributed misleading data about rival products.

Some of the shareholders who have petitioned the court claim that company officers at Teva are responsible for the violations and have a fiduciary duty of care under the law.

"The facts detailed below represent an indication that senior people at Teva acted unlawfully, in a way seen to be manipulative and deliberate, and likely to cause severe damage to the company, or at least were severely negligent," the petition from Lightcom (Israel) Ltd. and Revital Strugano, filed through Advs. Shachar Ben Meir, Renan Gersht, Ophir Naor, Adi Granot, and Yitzhak Aviram, states.

The shareholders are requesting that Teva should discover documents relating to the EU Commission investigation and to the extension of the patent on Copaxone for the purposes of filing a derivative action, a procedure whereby, when the directors of a company fail to sue company officers for damage to the company, shareholders can act. If the claims in a derivative action are upheld, any compensation is paid to the company.

Copaxone is the most widely used treatment for multiple sclerosis, and was Teva’s flagship product for years. In recent years, its contribution to Teva’s profits has declined substantially, as generic competition entered the market. Whereas in 2014 Copaxone accounted for 21% of Teva’s revenue, by 2019 the proportion had fallen to 6%.

Following the announcement by the EU Commission, Teva said in a statement: "We regret that the EU Commission has decided to continue with the investigation of Teva. The Commission’s declaration is a disappointment to Teva, which cooperated intensively with the Commission from the moment that it learned of the investigation in 2019. Teva will defend itself vigorously, and continues its discussions with the Commission to resolve the matter. Teva remains committed to the legal conduct of our business and to the mission of providing accessibility to medicines for millions of people."

In response to the court petition filed by shareholders for the discovery of documents, Teva stated: "Teva will respond through the accepted channels in the court after the requests are submitted to Teva."

Published by Globes, Israel business news - en.globes.co.il - on October 20, 2022.

© Copyright of Globes Publisher Itonut (1983) Ltd., 2022.

Teva drug Copaxone  credit: Tamar Matsafi
Teva drug Copaxone credit: Tamar Matsafi
Microsoft campus in Herzliya  credit; Eyal Izhar Microsoft: Exempt Israel from AI-chip export restrictions

Israel is among countries mentioned in a blog post by Microsoft vice chair and president Brad Smith criticizing the restrictions.

Paz gas station credit: Tali Bogdanovsky Gasoline prices in Israel to fall Saturday night

The maximum price of government price controlled 95 octane gasoline at self-service pumps in Israel will fall on Saturday at midnight March 2, 2025, by NIS 0.08 per liter to NIS 7.23 per liter.

Tel Aviv credit: Shutterstock Tel Aviv master plan sees 600,000 residents by 2035

The Tel Aviv District Planning and Building Committee has approved for deposit the TA/5500 master plan for Tel Aviv-Yafo.

Mizrahi Tefahot Bank  credit: Eyal Izhar Mizrahi Tefahot to pay huge dividend on record 2024 profit

The bank reported net profit of NIS 5.5 billion last year, up 11% from NIS 4.9 billion in 2023.

Sheba, Tel Hashomer Hospital Photo: Tamar Matsafi Israel's Sheba climbs in "Newsweek" world hospital top ten

Last year "Newsweek" ranked Sheba Medical Center in ninth place and previously it was in tenth place.

Cyberattack  credit: Shutterstock Israel second most targeted country for cyberattacks

The report by Radware found that Israel suffered 1,550 cyberattacks in 2024, second only to Ukraine which suffered 2,052 attacks.

BIG Fashion Glilot credit: Dror Marmor Israel's biggest mall opens Thursday

BIG Fashion Glilot strip mall is in Ramat Hasharon's new office park, adjacent to Cinema City Glilot.

Tesla Model Y credit: Shutterstock Can Tesla stage a comeback in Israel in 2025?

After taking Israel by storm four years ago, Tesla has gradually lost market shares to Chinese rivals but this trend could change this year.

Ghost jobs illustration: Tali Bogdanovsky 10% of Israeli tech vacancies are ghost jobs

Ethosia CEO Eyal Solomon says the proportion of "ghost" jobs - vacancies that have been advertised but not filled and continue to appear on the company's website - has jumped dramatically in recent years.

Prime Minister Benjamin Netanyahu and Transport Minister Miri Regev credit: Marc Israel Sellem Jerusalem Post Jerusalem Red Line extension awaits ribbon cutting

Opening the light rail extension has been delayed while a date is found for a ceremony attended by Prime Minister Benjamin Netanyahu and Transport Minister Miri Regev.

Tel Aviv light rail Light rail fares in Israel jump 33.3%

Bus fares will also rise 33.3% after the 2025 budget is passed.

Quantum Machines founders credit: Eyal Izhar Israeli co Quantum Machines raises $170m

Sources say that the company's valuation, which before the latest round was $520 million, has now risen to $670 million.

Pay cuts illustration: Shutterstock Treasury plans pay cuts for doctors, teachers, and civil servants

The move is intended to ensure that the budget savings target of NIS 5 billion shekels in 2025 is achieved, as part of efforts to reduce the state budget deficit.

Shekel credit: Shutterstock Vladirina 32 Shekel weakens after BoI rate call

Poria Financial Planning chairman Or Poria: There is growing uncertainty over the collapse of the hostage deal, and the increasing probability of renewed fighting in the south.

Daniel Aronovitz credit: Joseph Laor Insight Partners: $6b and still investing in Israel

Insight Partners newly appointed Israel partner Daniel Aronovitz tells "Globes" about the US firms plans for Israel and reveals the huge extent of past investment.

Bank of Israel Governor Amir Yaron credit: Eyal Izhar, Tali Bogdansky BoI Governor: We hope for two rate cuts in second half

Bank of Israel Governor Prof. Amir Yaron tells "Globes" he remains concerned about inflation, higher demand than supply, and real estate balloon loans.

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018